Patents by Inventor Shanzhong JIAN

Shanzhong JIAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof
    Patent number: 11548868
    Abstract: Disclosed herein are compounds of formula I and/or a stereoisomer, stable isotopologue, and/or pharmaceutically acceptable salts thereof; and therapeutic uses of these compounds, which are inhibitors of tryptophan 2, 3-dioxygenase 2 (TDO2) and/or indoleamine 2, 3-dioxygenase 1 (IDO1), potentially useful in the treatment of diseases treatable, such as cancers.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: January 10, 2023
    Assignee: JS Innopharm (Shanghai) Ltd.
    Inventors: Jintao Zhang, Wen Xu, Shanzhong Jian, Ao Li, Qun Li
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
    Publication number: 20220220128
    Abstract: (I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate thereof; and therapeutic uses of these compounds, which are inhibitors of rearranged during transfection (RET), potentially useful in the treatment of RET-associated diseases, such as RET-associated cancers.
    Type: Application
    Filed: June 9, 2020
    Publication date: July 14, 2022
    Inventors: Qun LI, Jintao ZHANG, Shanzhong JIAN, Ao LI, Wen XU
  • Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
    Patent number: 11242334
    Abstract: (I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and therapeutic uses of these compounds, which are kinase inhibitors potentially useful in the treatment of diseases treatable, such as cancers, as well as pharmaceutical compositions, comprising a compound of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: February 8, 2022
    Assignee: JS Innopharm (Shanghai) Ltd.
    Inventors: Jintao Zhang, Wen Xu, Shanzhong Jian, Qun Li
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
    Publication number: 20210188868
    Abstract: The present disclosure provides a compound of Formula (I) and/or a stereoisomer, a tautomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and therapeutic uses of these compounds. They are kinase inhibitors potentially useful in the treatment of diseases treatable, such as cancers. Also disclosed herein is a pharmaceutical composition, comprising a compound of Formula (I) and/or a stereoisomer, a tautomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 20, 2019
    Publication date: June 24, 2021
    Inventors: Qun LI, Jintao ZHANG, Shanzhong JIAN, Wen XU, Ao LI
  • HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
    Publication number: 20200339533
    Abstract: Disclosed herein are compounds of formula I and/or a stereoisomer, stable isotopologue, and/or pharmaceutically acceptable salts thereof; and therapeutic uses of these compounds, which are inhibitors of tryptophan 2, 3-dioxygenase 2 (TDO2) and/or indoleamine 2, 3-dioxygenase 1 (IDO1), potentially useful in the treatment of diseases treatable, such as cancers.
    Type: Application
    Filed: October 19, 2018
    Publication date: October 29, 2020
    Inventors: Jintao Zhang, Wen Xu, Shanzhong Jian, Ao Li, Qun Li
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
    Publication number: 20200239438
    Abstract: (I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and therapeutic uses of these compounds, which are kinase inhibitors potentially useful in the treatment of diseases treatable, such as cancers, as well as pharmaceutical compositions, comprising a compound of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: August 15, 2018
    Publication date: July 30, 2020
    Inventors: Jintao ZHANG, Wen XU, Shanzhong JIAN, Qun LI
  • Pyrazolo fused heterocyclic compounds as ERK inhibitors
    Patent number: 10696687
    Abstract: Disclosed herein is a compound of formula (I) and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors. They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition, comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: June 30, 2020
    Assignee: Changzhou Jiekai Pharmatech Co., LTD.
    Inventors: Jintao Zhang, Wen Xu, Shanzhong Jian
  • Heterocyclic compounds as ERK inhibitors
    Patent number: 10479791
    Abstract: Disclosed herein is a compound of formula I and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors: They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: November 19, 2019
    Assignees: CHANGZHOU JIEKAI PHARMATECH CO. LTD, JS INNOPHARM (SHANGHAI) LTD
    Inventors: Jintao Zhang, Wen Xu, Shanzhong Jian
  • PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS
    Publication number: 20180237450
    Abstract: Disclosed herein is a compound of formula (I) and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors. They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition, comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: August 20, 2015
    Publication date: August 23, 2018
    Applicant: CHANGZHOU JIEKAI PHARMATECH CO., LTD.
    Inventors: Jintao ZHANG, Wen XU, Shanzhong JIAN
  • HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS
    Publication number: 20180179211
    Abstract: Disclosed herein is a compound of formula I and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors: They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 3, 2015
    Publication date: June 28, 2018
    Applicants: CHANGZHOU JIEKAI PHARMATECH CO. LTD, JS INNOPHARM (SHANGHAI) LTD
    Inventors: Jintao ZHANG, Wen XU, Shanzhong JIAN